RESEARCH CENTERS

Research Center for Biopharmaceutical
Innovation and Technology

상단이미지

Research Center for Biopharmaceutical Innovation
and Technology

Research Center for Biopharmaceutical Innovation and Technology peptide/protein/antibody/cell-based biopharmaceutical candidates. and delivery source technology research, gene-based cancer, infectious disease, metabolic/inflammatory/immune disease diagnosis/prevention/treatment nanotechnology, cell therapy and We are performing source technology related to regenerative medicine.
Staff organizational chart

전대원 교수

DirectorJun Dae-won
Brief history
Department of Gastroenterology, College of Medicine
(Concurrent) Professor, Department of Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University
(Concurrent) Professor, Department of Medical and Digital Engineering, College of Engineering
Research topics
Research on peptide / protein / antibody / cell-based biopharmaceutical candidates and original technology for drug delivery
Nanotechnology for gene-based diagnosis/prevention/treatment of cancers, infectious diseases, metabolic/inflammatory/immune diseases
Original technology related to cell therapy and regenerative medicine
Faculty & Researcher
Collge of Medicine (19 individuals)
강주섭, 조석현, 이영호, 최찬범, 전대원, 황정욱, 문진화, 이진규, 윤영은, 박계영, 오요한, 윤재훈, 조정기, 이창훈, 안성준, 허준호, 황우창, 최성지, 윤아일린
College of Engineering (4 individuals)
전진용, 김인욱, 윤아름, 윤채옥
Collge of Natural Sciences (1 individuals)
김철근
Research Institute (3 individuals)
장은경, 김수아, 조철호
Major research topics
  • Development of new drug screening platform based on bio–big data
  • Research on peptide/protein/antibody/cell-based biopharmaceutical candidates and delivery-related original technology
  • Nanotechnology for gene-based cancer, infectious disease, metabolic/inflammatory/immune disease diagnosis/prevention/treatment
  • Original technology related to cell therapy and regenerative medicine
  • Synthetic drug development
    Daegu Cheombok Complex, Ewha Womans University College of Pharmacy and regular meeting related to synthetic new drugs (once a month)
    Application for patent for Daegu Cheombokdanji No. 1 synthetic new drug
    Concluded a confidentiality agreement with Theragen Bio to discuss out-licensing of related new drugs
    Future Medicine first in class drug phase 2a domestic multi-center clinical study commissioned
    After J2H first in class drug phase 1 was completed, a domestic multi-center clinical phase 2 study was requested.
    Biotoxtech Korea's first commercial primate center establishment related business agreement and promotion of joint work for establishment of primate model
  • RNA-based New Drug Development Team
    Started research meeting for RNA-based new drug development for 2 targets
  • New drug development team based on digital therapy
    Completion of work cooperation and division of work for the development of Gaji Lab and digital therapeutics
    Digital therapeutics-based clinical research from November 2022
    2023. 2. 6. Signed MOU with Gaji Lab for the development of digital therapeutics
검색 닫기